Protection Against Hyperglycemia in Female Nonobese Diabetic Mice Treated with 15-Deoxyspergualin

Abstract

The effects of 15-deoxyspergualin (SDS), a newly described immunosuppressive agent, have been studied on the development of diabetes in female NOD mice. 15-DS treatment was started two weeks after weaning i.e. at five weeks of age. The mice received either one daily intraperitoneal injection of 15-DS (2.5 mag body weight) or saline for two weeks. The mice were then injected every third day up to eight months of age for evaluation of the diabetes incidence. In another set of experiments the mice were treated up to three months of age, whereafter islet insulin release, islet insulin content and DNA content was measured together with an evaluation of spleen cell proliferation rates. Different spleen cell subsets were studied directly after the two weeks of daily injections.

In the saline group 8 out of 9 mice developed diabetes, whereas only 4 out of 11 of the 15-DS treated mice became diabetic (p<0.05). There was no difference between the groups in islet insulin release in response to glucose, however, the islet insulin release increased after one week in culture. The 15-DS treatment did not affect the insulin or DNA content of the isolated islets or the insulin concentration in the pancreas. No detectable changes in the relative number of CD4* and CD8* T-cell subsets in the spleen were seen and there were no obvious differences in splenocyte proliferation rates. The histological examinations of the pancreatic glands showed gradual increasing signs of islet inflammation with age and 15-DS could apparently not prevent this. In order to gain further information on the immunosuppressive action of 15-DS, the drug was injected for 14 d in cyclophosphamide treated female NOD mice. These experiments showed that none of the 11 mice given 15-DS became diabetic while 6 out of 10 of the mice given saline did become diabetic. The present results thus suggest that 15-DS partially prevents the occurrence of diabetics in NOD mice. Presumably this is achieved by interfering with the autoimmune mediated β-cell destruction, through a mechanism. which remains to be identified.

Key Words:

• Nonobese diabetic mouse
• insulin-dependent diabetes mellitus 15-deoxyspergualin
• immunosuppression
• cyclophosphamide